NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Forecast, Price & News $0.98 +0.02 (+2.47%) (As of 03:27 PM ET) Add Compare Share Share Today's Range$0.93▼$1.0250-Day Range$0.80▼$1.1352-Week Range$0.77▼$2.42Volume167,752 shsAverage Volume233,178 shsMarket Capitalization$51.16 millionP/E RatioN/ADividend YieldN/APrice Target$2.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Assembly Biosciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside125.7% Upside$2.17 Price TargetShort InterestHealthy0.31% of Shares Sold ShortDividend StrengthN/ASustainability-0.71Upright™ Environmental ScoreNews Sentiment-0.01Based on 26 Articles This WeekInsider TradingSelling Shares$55,227 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector166th out of 983 stocksPharmaceutical Preparations Industry72nd out of 486 stocks 3.2 Analyst's Opinion Consensus RatingAssembly Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.17, Assembly Biosciences has a forecasted upside of 125.7% from its current price of $0.96.Amount of Analyst CoverageAssembly Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.31% of the outstanding shares of Assembly Biosciences have been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 5.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAssembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Assembly Biosciences is -0.71. Previous Next 1.7 News and Social Media Coverage News SentimentAssembly Biosciences has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Assembly Biosciences this week, compared to 22 articles on an average week.Search Interest2 people have searched for ASMB on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,227.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 34.02% of the stock of Assembly Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to grow in the coming year, from ($1.33) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Assembly Biosciences (NASDAQ:ASMB) StockAssembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.Read More Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ASMB Stock News HeadlinesJune 2, 2023 | msn.comIrish premier hopes to see Stormont Assembly restored by SeptemberJune 2, 2023 | msn.comPlateau Assembly suspends LG chairmen, councillorsJune 2, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.June 2, 2023 | foxnews.comTrinidadian ambassador elected UN General Assembly presidentJune 1, 2023 | sports.yahoo.comCalifornia Assembly passes bill allowing college athletes to be paid by schoolsJune 1, 2023 | msn.comCalifornia Assembly ignores Meta’s threat, votes to pass the Journalism Preservation ActJune 1, 2023 | news.yahoo.comFive Republicans focus on guns, taxes, sex-ed in heated race for 24th District AssemblyJune 1, 2023 | msn.comLucas Co. to hold Toledo Jeep Assembly Plant hiring eventJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. June 1, 2023 | msn.comWhy Creative Assembly Wanted to Set the Next Total War Game in EgyptJune 1, 2023 | abcnews.go.comTrinidad's Francis elected next leader of UN General AssemblyJune 1, 2023 | msn.comWhat’s in, what’s out as the General Assembly wraps upMay 31, 2023 | msn.com'Public Will Not Fall For This': BJP After Rajasthan CM Ashok Gehlot's Big Relief On Electricity Bills Ahead Of Assembly ElectionsMay 31, 2023 | msn.comNYS Assembly faces paper plane assault from Good Cause eviction activistsMay 31, 2023 | msn.com9th Taraba Assembly processed 40 bills in four years – SpeakerMay 31, 2023 | americanbankingnews.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 5.5% in MayMay 30, 2023 | msn.comGender identity amendment rejected by Assembly; Lombardo vetoes 2 billsMay 30, 2023 | msn.comGeneral Motors’ Fort Wayne Assembly produces 10 millionth vehicleMay 30, 2023 | msn.comAfrica: 76th World Health Assembly Adopts First Ever Resolution On Drowning PreventionMay 30, 2023 | msn.com(LEAD) Arrest motion for 2 lawmakers over 'cash envelope' scandal to be reported to National AssemblyMay 29, 2023 | msn.comAssembly Bill Would Require Countywide Vote for Fallbrook, Rainbow to Exit Water AuthorityMay 29, 2023 | msn.comNational Assembly to revote on controversial nursing act after Yoon's vetoMay 29, 2023 | msn.comAkatsi North Education Directorate receives 250 dual desks from AssemblyMay 29, 2023 | msn.comCongress to continue winning spree, to win 150 seats in MP Assembly polls, says Rahul GandhiMay 29, 2023 | msn.comLawmakers lament as Plateau Assembly closure enters eighth weekMay 28, 2023 | msn.comGray’ s first bill passes State Assembly, could help Ogdensburg Bridge and Port AuthorityMay 27, 2023 | msn.comWorld Health Assembly adopts Israeli-led resolution on rehabilitation in health systemsSee More Headlines ASMB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASMB Company Calendar Last Earnings3/22/2023Today6/02/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ASMB CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees102Year Founded2005Price Target and Rating Average Stock Price Forecast$2.17 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+125.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.79% Return on Assets-79.09% Debt Debt-to-Equity RatioN/A Current Ratio8.00 Quick Ratio8.00 Sales & Book Value Annual Sales$6.25 million Price / Sales8.01 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.71Miscellaneous Outstanding Shares52,120,000Free Float49,828,000Market Cap$50.04 million OptionableOptionable Beta0.68 Social Links Key ExecutivesJason A. OkazakiPresident, Chief Executive Officer & DirectorWilliam DelaneyChief Scientific OfficerJohn O. GundersonSecretary, Vice President & General CounselMichele AndersonChief Development OfficerNicole S. WhiteChief Manufacturing OfficerKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXParatek PharmaceuticalsNASDAQ:PRTKNektar TherapeuticsNASDAQ:NKTRNRx PharmaceuticalsNASDAQ:NRXPSELLAS Life Sciences GroupNASDAQ:SLSView All CompetitorsInsiders & InstitutionsJohn G MchutchisonSold 25,972 sharesTotal: $27,010.88 ($1.04/share)Jason A OkazakiSold 6,561 sharesTotal: $6,823.44 ($1.04/share)Jeanette M BjorkquistSold 274 sharesTotal: $284.96 ($1.04/share)Hudson Bay Capital Management LPSold 75,000 shares on 5/16/2023Ownership: 1.823%Two Sigma Investments LPBought 38,303 shares on 5/15/2023Ownership: 0.073%View All Insider TransactionsView All Institutional Transactions ASMB Stock - Frequently Asked Questions Should I buy or sell Assembly Biosciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks. What is Assembly Biosciences' stock price forecast for 2023? 3 Wall Street research analysts have issued 1-year target prices for Assembly Biosciences' stock. Their ASMB share price forecasts range from $1.50 to $3.00. On average, they anticipate the company's stock price to reach $2.17 in the next twelve months. This suggests a possible upside of 125.7% from the stock's current price. View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts. How have ASMB shares performed in 2023? Assembly Biosciences' stock was trading at $1.30 at the beginning of the year. Since then, ASMB stock has decreased by 26.2% and is now trading at $0.96. View the best growth stocks for 2023 here. Are investors shorting Assembly Biosciences? Assembly Biosciences saw a decline in short interest in May. As of May 15th, there was short interest totaling 161,300 shares, a decline of 5.5% from the April 30th total of 170,600 shares. Based on an average trading volume of 214,900 shares, the short-interest ratio is presently 0.8 days. View Assembly Biosciences' Short Interest. When is Assembly Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ASMB earnings forecast. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings results on Wednesday, March, 22nd. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.10. What ETF holds Assembly Biosciences' stock ? ETFMG Treatments Testing and Advancements ETF holds 16,315 shares of ASMB stock, representing 0.07% of its portfolio. What is John McHutchison's approval rating as Assembly Biosciences' CEO? 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC). What is Assembly Biosciences' stock symbol? Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB." Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.08%), Hudson Bay Capital Management LP (1.82%), Platinum Investment Management Ltd. (1.71%), Renaissance Technologies LLC (1.47%), Federated Hermes Inc. (0.70%) and Dimensional Fund Advisors LP (0.55%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Timothy A Springer, William E Iv Delaney and William E Iv Delaney. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Assembly Biosciences' stock price today? One share of ASMB stock can currently be purchased for approximately $0.96. How much money does Assembly Biosciences make? Assembly Biosciences (NASDAQ:ASMB) has a market capitalization of $50.04 million and generates $6.25 million in revenue each year. The biopharmaceutical company earns $-93,090,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. How many employees does Assembly Biosciences have? The company employs 102 workers across the globe. How can I contact Assembly Biosciences? Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.assemblybio.com. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at lglaser@assemblybio.com, or via fax at 646-706-5101. This page (NASDAQ:ASMB) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.